Salvia divinorum, a plant used for centuries by the Mazatecan culture and now a recreational drug, produces potent hallucinogenic effects. Its main compound, salvinorin A, is the first highly selective non-nitrogenous kappa opioid receptor agonist. Animal studies show rapid onset, short half-lives, and no evidence of short- or long-term toxicity. Salvinorin A appears promising for new treatments of central nervous system illnesses, but further research is needed to understand the plant's medicinal properties and inform legislation.
Ayahuasca, a traditional medicine known for its hallucinogenic properties, has shown promising effects in treating mental health issues. In a study involving 100 participants, 65% reported significant reductions in anxiety and depression after consuming ayahuasca, attributed to its unique alkaloid composition. Additionally, berberine, another alkaloid, demonstrated potential in enhancing the therapeutic effects of ayahuasca by modulating biological pathways. This highlights the importance of integrating traditional medicine with modern pharmacology to unlock new avenues for mental health treatment.
Indole alkaloids such as ibogaine and mitragynine activate μ-opioid receptors as biased full or partial agonists that recruit β-arrestin much less than non-biased agonists. Because β-arrestin recruitment is linked to adverse effects like respiratory depression, this biased activation may limit those effects. The molecular mechanism likely involves the indole structure altering the spatial orientation of amino acid residues in transmembrane regions 2 and 3 and extracellular helix 8. These naturally occurring compounds may provide a scaffold for developing new opioid modulators with an improved risk-to-benefit ratio.